DKCM
CRL icon

Davidson Kempner Capital Management’s Charles River Laboratories CRL Stock Holding History

Davidson Kempner Capital Management’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-162,500
Closed -$17.6M – 167
2017
Q3 		$17.6M Buy
162,500
+62,500
+63% +$6.42M 0.23% 75
2017
Q2 		$10.1M Buy
+100,000
New +$9.2M 0.14% 108

Other funds holding CRL

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $33.3B AUM 44.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $100B AUM 36.93% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Davidson Kempner Capital Management's CRL Position: Q4 2017 in Review

Davidson Kempner Capital Management sold out of Charles River Laboratories (CRL) in Q4 2017, closing a stake of 162,500 shares — an estimated $17.6M sold.

Davidson Kempner Capital Management first reported a position in CRL in Q2 2017 and held it in 2 quarters. The position peaked at $17.6M in Q3 2017. 339 funds tracked by Wall St. Rank hold CRL as of Q4 2017.

  • Davidson Kempner Capital Management reported no remaining Charles River Laboratories position as of Q4 2017 after selling out during the quarter.
  • Davidson Kempner Capital Management sold 162,500 Charles River Laboratories shares in Q4 2017, an estimated $17.6M.
  • Davidson Kempner Capital Management first reported a position in Charles River Laboratories in Q2 2017 and held it in 2 quarters.
  • Davidson Kempner Capital Management's Charles River Laboratories position peaked at $17.6M in Q3 2017.
  • 339 funds tracked by Wall St. Rank held Charles River Laboratories as of Q4 2017.

Based on Davidson Kempner Capital Management's 13F filing for Q4 2017, filed 14 Feb 2018.